Drug Profile
Research programme: Ral protein inhibitors - NantBioscience/University of Colorado
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator NantBioScience; University of Colorado at Denver
- Developer University of Colorado at Denver
- Class
- Mechanism of Action Ral GTP-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Cancer in USA
- 15 Sep 2014 Early research in Cancer in USA (unspecified route)